Boomerang Medical is a women-led bioelectronic medicine company headquartered on the El Camino Hospital campus in Mountain View, California, led by CEO Heather Simonsen. The company develops implantable neuromodulation treatments for autoimmune diseases and is advancing BOOM-IBD2, described as the first pivotal trial of implantable neuromodulation in inflammatory bowel disease with an initial focus on ulcerative colitis. It completed a 40-patient feasibility study in Crohn's disease and ulcerative colitis, and those results informed the design of BOOM-IBD2. Boomerang notes that sacral neuromodulation has a long safety record, with more than 500,000 procedures performed worldwide. The company is a Company-In-Residence at Fogarty Innovation and was recognized as an "Emerging Leader in IBD" by the Crohn’s & Colitis Foundation. It plans to use the newly raised funds to advance the BOOM-IBD2 pivotal trial. Boomerang Medical develops a neuromodulation technology that harnesses the body’s peripheral wiring to manage inflammation and immune response for autoimmune diseases. The company is clinical-stage and recently received FDA authorization to commence the Boomerang Clinical Trial for patients with Inflammatory Bowel Disease (IBD). Boomerang is using its device-oriented approach to target hard-to-treat autoimmune conditions, with an initial focus on IBD (including Crohn’s disease and ulcerative colitis). Management is led by President and CEO Heather Simonsen, and the company is a Company‑In‑Residence at Fogarty Innovation on the El Camino Health campus. Boomerang plans to use the new financing to advance clinical studies of its neuromodulation platform. The company is headquartered in Mountain View, Calif.

Total raised

$35M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2025